Jens Kurth
Bioinformatics & Systems Biology
Wesley C Van?Voorhis
France
Biography
Dr. Jens Kurth has 20 years of experience in biotech start up and Pharma Industry at Novartis and Baxter in pre- and clinical development of small molecules, biologics, gene and cell based therapies incl. technical development of biologics and advanced therapies. He is highly skilled with a track record in translating innovative concepts and technologies into marketable products. Prior to founding Vivet Therapeutics, Jens Kurth was heading preclinical development incl. technical development as Chief Technology Officer at Anokion SA, in Lausanne, Switzerland since its inception in 2014. Focus was the development of inducing immune tolerance to therapeutic proteins and antigens in auto immune diseases. He was a leading member in entering into a collaboration agreement with Astellas, Japan. At Baxter in Austria, Jens Kurth was heading the process development and manufacturing improvement unit for plasma derived biologics. At Novartis in Switzerland and Japan headquarters he held various senior positions in global project management leading programs from research to 2 NDA and 3 BLA submissions in the US; EU and Japan.
Research Interest
Bioinformatics & Systems Biology
